ClinicalTrials.gg
RecruitingNCT07232485RISEUpdated Oct 21, 2026

Retinal Imaging for Systemic Inflammation in Endometriosis

An observational study in Endometriosis, sponsored by University of Edinburgh. Recruiting at 1 site in United Kingdom. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by University of Edinburgh · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Endometriosis with a site in United Kingdom — 10 open to participants now, 11 under way, none of them phase 3. Endometriosis · United Kingdom.

Planned enrollment
6th of 12
100 · median 100
Started
2025
with 5 others
Observational
12 of 25
8 open now
Primary completion
2029-08
later than 9 of 10 live
Registered
20th of 25
by date
Lead sponsor
6 of 25
University of Edinburgh

Among the 25 studies in Endometriosis with a site in United Kingdom, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2025, is one of 12 observational ones, reaches primary completion later than 9 of the 10 other live ones, and was the 20th registered.

Endometriosis

924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.

Browse Endometriosis studies →

Open to participants now

10 of the 25 studies in Endometriosis with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Endometriosis with a site in United Kingdom, or all of them as a file.
02

Study summary

There is increasing evidence that examining our eyes can tell us a lot of information about our health, and systemic diseases. Our plan is to compare the images taken of the back of eyes of women who have endometriosis with those of women who don't. We want to study what eyes can reveal about endometriosis by analyzing the retinal images from a simple noninvasive eye scan, that is already being routinely used to provide immediate clinical information in other groups of patients (eg. diabetic eye screening).

Read the detailed description

What this study is about Endometriosis is now understood to affect the whole body, not just the pelvis. Many individuals with endometriosis show signs of low-grade systemic inflammation. The eye offers clinicians a clear, painless window on tiny blood vessels. Modern retinal scans can measure structure and blood flow at the back of the eye within minutes. This study will test whether retinal scans can serve as a non-invasive read-out of systemic inflammation in endometriosis. If successful, this approach could support assessment and longitudinal monitoring.

What will happen in the study

This is an exploratory case-control study. Women with endometriosis and age-matched women without endometriosis will be invited for a research visit at the Queen's Medical Research Institute (QMRI), Edinburgh. All participants will undergo the following retinal imaging:

Optical Coherence Tomography (OCT): a quick scan showing retinal and choroidal layers.

OCT Angiography (OCT-A): a map of tiny retinal vessels without dye injections. Ultra-widefield (UWF) imaging (Optos): a large-field retinal image. Scans are painless, non-invasive, and similar to routine eye assessments. The eye-imaging component takes about 30-40 minutes; the entire visit lasts about 1 hour.

Participants with endometriosis will also complete a brief endometriosis-specific quality-of-life questionnaire (EHP-30) before imaging. A small blood sample (up to 40 mL) may be taken to measure C-reactive protein (CRP) and other inflammation markers immediately or in the future (with consent). Any surplus samples may be stored securely for related research. Healthy volunteers attend a single visit only. Participants with endometriosis may be invited for repeat assessments after treatment - for example, 3 - 6 months after surgery or initiation of new hormonal therapy, or 4 - 8 weeks after completing an endometriosis-related clinical trial - to repeat the same assessments.

Burden, risks, and discomforts Retinal imaging does not use ionising radiation and is considered low risk. Possible short-lived effects include eye strain or mild headache from fixation on a target light. Venepuncture may cause brief discomfort or mild bruising. Breaks will be scheduled if needed, and expected effects will be recorded in the study file.

Measurements and analyses Scan-derived measurements will include retinal thickness, retinal nerve fibre layer thickness, macular volume, choroidal thickness, and retinal micro-vessel features. Between-group differences (endometriosis vs controls) will be analysed. Associations with blood inflammation markers will be assessed, and changes after treatment will be evaluated.

Data handling and confidentiality Study data are recorded in a case report form and entered into a secure REDCap database hosted by the University of Edinburgh. Personal details (e.g., contact information) are stored separately on secure systems with restricted access. Research data are pseudonymised using study ID codes. Data are retained and archived according to University/NHS Sponsor policies and UK data-protection law. Selected anonymised data and samples may be shared with academic or industry partners as described in the consent documents. Participation is voluntary, and participants may withdraw at any time; data collected up to withdrawal are retained for scientific and regulatory integrity.

Oversight and approvals The study is co-sponsored by the University of Edinburgh and NHS Lothian (ACCORD) and conducted in line with Good Clinical Practice (GCP) and all required approvals. Monitoring or audit may occur according to Sponsor procedures. The study ends after the last participant's last visit; a summary will be provided to the Research Ethics Committee.

03

Conditions studied

  • Endometriosis

Browse trials for

Keywords

  • Endometriosis
  • Retinal imaging
  • Systemic inflammation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This is a matched case-control study. We will recruit 50 women with endometriosis (case) and 50 women matched for age without endometriosis (controls).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with a previous surgical or imaging diagnosis of endometriosis

    • Pre-menopausal women and those assigned female at birth
    • Aged 18 years and over
    • A past surgical or imaging diagnosis of endometriosis within the last 5 years from date of consent
    • Ability to understand and willingness to sign the form
  2. Healthy volunteers

    • Women and those assigned female at birth
    • Aged 18 years and over
    • No history of endometriosis or chronic pelvic pain
    • Ability to understand and willingness to sign the informed consent form

Exclusion criteria

Exclusion Criteria:

  1. Participants with a previous surgical or imaging diagnosis of endometriosis

    • The subject has donated blood (450 ml) within the last 4 weeks
    • Known reproductive tract
    • Ocular Diseases:

      • Subjects with clinically diagnosed glaucoma, optic neuropathy, optic neuritis, cataracts, or other conditions that affect the ocular structures.
      • Subjects with age-related macular degeneration, retinal vascular diseases, or other retinal disorders.
      • Subjects with any other ocular conditions that may influence the retinal or optic nerve structure.
    • Refractive Errors:

      • Subjects with high myopia (>6 diopters) or high hyperopia (>3 diopters).
      • Subjects with significant astigmatism (>2 dioptres) or other refractive errors.
    • Ocular Surgery History: Subjects with a history of ocular surgery, particularly involving the lens, cornea, retina, or optic nerve (e.g., laser vision correction, retinal surgeries, etc.).
    • Subjects with significant ocular trauma, corneal abnormalities, or active ocular infections that may interfere with OCT imaging.
    • Subjects with diabetes mellitus
  2. Healthy volunteers

    • The subject has donated blood (450 ml) within the last 4 weeks
    • Known reproductive tract malignancy
    • A history of symptoms suggestive of endometriosis or chronic pelvic pain
    • Ocular Diseases:

      • Subjects with clinically diagnosed glaucoma, optic neuropathy, optic neuritis, cataracts, or other conditions that affect the ocular structures.
      • Subjects with age-related macular degeneration, retinal vascular diseases, or other retinal disorders.
      • Subjects with any other ocular conditions that may influence the retinal or optic nerve structure.
    • Refractive Errors:

      • Subjects with high myopia (>-6 dioptres) or high hyperopia (>+6 dioptres).
      • Subjects with significant astigmatism (>2 dioptres) or other refractive errors.
    • Ocular Surgery History: Subjects with a history of ocular surgery, particularly involving the lens, cornea, retina, or optic nerve (e.g., laser vision correction, retinal surgeries, etc.).
    • Subjects with significant ocular trauma, corneal abnormalities, or active ocular infections that may interfere with OCT imaging.
    • Subjects with diabetes mellitus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Endometriosis women

    Pre-menopausal women with a previous surgical or imaging diagnosis of endometriosis

  • Healthy volunteers

    Pre-menopausal women with no history of endometriosis or chronic pelvic pain

06

What researchers measure

Primary outcomes

  1. Choroidal Thickness (Optical Coherence Tomography, Heidelberg SPECTRALIS)

    Choroidal thickness quantified from OCT cross-sectional scans using the Heidelberg SPECTRALIS platform to compare endometriosis cases with matched controls at baseline. Unit of Measure: micrometers (µm).

    Time frame: Baseline

  2. Retinal Thickness (Optical Coherence Tomography, Heidelberg SPECTRALIS)

    Full-thickness retinal measurements derived from OCT (Heidelberg SPECTRALIS) for between-group comparison at baseline. Unit of Measure: micrometers (µm).

    Time frame: Baseline

  3. Retinal Nerve Fiber Layer (RNFL) Thickness (Optical Coherence Tomography, Heidelberg SPECTRALIS)

    RNFL thickness obtained on OCT for baseline comparison between endometriosis and matched controls. Unit of Measure: micrometers (µm).

    Time frame: Baseline

  4. Macular Volume (Optical Coherence Tomography, Heidelberg SPECTRALIS)

    Macular volume derived from OCT volume scans for baseline between-group comparison. Unit of Measure: cubic millimeters (mm³).

    Time frame: Baseline

  5. Retinal Vessel Density (Optical Coherence Tomography Angiography, Heidelberg SPECTRALIS)

    OCT-A-based vessel density (non-invasive angiography) used to characterize retinal microvasculature for baseline between-group comparison. Unit of Measure: percent (%).

    Time frame: Baseline

Secondary outcomes

  1. Change from Baseline in Choroidal Thickness

    Within-participant change from baseline to the relevant post-intervention time point(s). Unit of Measure: micrometers (µm).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  2. Change from Baseline in Retinal Thickness

    Within-participant change from baseline to post-intervention. Unit of Measure: micrometers (µm).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  3. Change from Baseline in RNFL Thickness

    Description: Within-participant change from baseline to post-intervention. Unit of Measure: micrometers (µm).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  4. Change from Baseline in Macular Volume

    Within-participant change from baseline to post-intervention. Unit of Measure: cubic millimeters (mm³).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  5. Change from Baseline in Retinal Vessel Density

    Within-participant change from baseline to post-intervention using OCT-A vessel density. Unit of Measure: percent (%).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  6. Correlation Between Serum C-reactive Protein and Choroidal Thickness (OCT)

    Association between serum CRP concentration (laboratory assay, mg/L) and choroidal thickness (OCT, µm). Pearson or Spearman as appropriate per analysis plan. Unit of Measure: correlation coefficient r (unitless).

    Time frame: Baseline and post intervention (3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline)

  7. Correlation Between Serum C-reactive Protein and Retinal Thickness (OCT)

    Association between serum CRP (mg/L) and retinal thickness (µm). Unit of Measure: correlation coefficient r (unitless).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  8. Correlation Between Serum C-reactive Protein and RNFL Thickness (OCT)

    Association between serum CRP (mg/L) and RNFL thickness (µm). Unit of Measure: correlation coefficient r (unitless).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  9. Correlation Between Serum C-reactive Protein and Macular Volume (OCT)

    Association between serum CRP (mg/L) and macular volume (mm³). Unit of Measure: correlation coefficient r (unitless).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

  10. Correlation Between Serum C-reactive Protein and Retinal Vessel Density (OCT Angiography)

    Association between serum CRP (mg/L) and retinal vessel density (%) from OCT-A. Unit of Measure: correlation coefficient r (unitless).

    Time frame: Baseline; and post-intervention at 3-6 months after surgery or new hormonal treatment; or 4-8 weeks after completion of an endometriosis-related clinical trial; assessments occur within up to 3 years of baseline.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — What IPD: De-identified participant-level datasets and surplus biological samples as applicable. With Whom/Conditions: Academic or industry partners, as described in the PIS/consent; no release of identifiable data; publications contain no personal data. How/Where: Secure transfer under data-sharing agreements; data stored in validated REDCap with controlled access.

Supporting information: Study protocol, Informed consent form

Time frame: Selected anonymised data and samples collected or generated by the study may be shared with academic or industry partners within the UK from the start of the study (expected start date: 01/10/2025). Research data will be archived and stored on secure servers hosted by The University of Edinburgh (in Data Store) for 10 years.

Access criteria: Who can access: Authorized study team and Co-Sponsor (University of Edinburgh/NHS Lothian) for conduct/monitoring/audit/archiving; Research Ethics Committee and regulators may inspect records. External academic/industry collaborators may receive selected anonymised participant-level data and anonymised surplus samples per PIS/consent; identifiable data are not released. What: De-identified eCRF data (demographics, clinical characteristics, retinal imaging metrics, questionnaire scores, lab reports) and, where applicable, anonymised surplus biosamples. How: Internal data stored in validated REDCap on secure University servers with user authentication; personal identifiers held separately; participants assigned unique study IDs (pseudonymised). External sharing only in anonymised form, under Sponsor approval and data-sharing agreements, with secure transfer. Data controller: Co-Sponsor; retention: ≥5 years for personal data, 10 years for research data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Aug 2029, 47 months after the start.

Of 158 non-industry observational studies under Endometriosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 47 months is above that.

Counting every sponsor, half of 185 studies reached it within 30 months; a quarter within 14 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2025
First posted
Nov 18, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Aug 2029
CompletionEst.
Sep 2029
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07232485
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Sep 3, 2025
Primary completion
Aug 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Oct 21, 2026

Study contacts

Kexin Dong
Contact
K.Dong-2@sms.ed.ac.uk
+447301394870
Andrew Horne
principal investigator · University of Edinburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion